Study: NovaTears effective, safe for dry eye disease

Novaliq GmbH announced Wednesday that its observational study for NovaTears OTC yielded positive results.

The study involved 30 participants who had symptoms of mild to moderate evaporative dry eye disease who utilized the eye drops, according to the release.

“All results of the study point toward excellent clinical performance, safety and very high convenience and acceptance of NovaTears for patients suffering from hyper-evaporative dry eye,” Philipp Steven, MD, PhD, the coordinating investigator of study NT-001, said in a company press release.

Specifically, the study was designed to assess lubrication of the ocular surface, stabilization of the tear film and relief of adverse symptoms, as well as tolerability and safety.

Results showed the improvement of tear film fluid and stability, unchanged tear osmolarity and decreased symptom severity. Additionally, the release stated that there were no changes in intraocular pressure or visual acuity.

Investigator Thomas Kaercher, MD, reported that he received encouraging feedback from his patients.

“Most of my patient experiences were very positive, and patients frequently requested to continue on NovaTears treatment following the study’s cessation,” he said in the release.

As detailed in the release, Novaliq is preparing for NovaTears to enter the market in several areas.